The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

ADEFOVIR     2-(6-aminopurin-9- yl)ethoxymethylphosphoni...

Synonyms: CHEMBL484, PubChem14227, SureCN49373, AGN-PC-00FYWF, DRG-0156, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of ADEFOVIR

 

High impact information on ADEFOVIR

 

Chemical compound and disease context of ADEFOVIR

 

Biological context of ADEFOVIR

 

Anatomical context of ADEFOVIR

 

Associations of ADEFOVIR with other chemical compounds

 

Gene context of ADEFOVIR

 

Analytical, diagnostic and therapeutic context of ADEFOVIR

References

  1. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Balzarini, J., Hao, Z., Herdewijn, P., Johns, D.G., De Clercq, E. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  2. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Egberink, H., Borst, M., Niphuis, H., Balzarini, J., Neu, H., Schellekens, H., De Clercq, E., Horzinek, M., Koolen, M. Proc. Natl. Acad. Sci. U.S.A. (1990) [Pubmed]
  3. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs. Thormar, H., Georgsson, G., Pálsson, P.A., Balzarini, J., Naesens, L., Torsteinsdóttir, S., De Clercq, E. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  4. Effect of weekly adefovir (PMEA) infusions on HIV-1 virus load: results of a phase I/II study. Kamp, W., Schokker, J., Cambridge, E., De Jong, S., Schuurman, R., De Groot, T., Boucher, C.A. Antivir. Ther. (Lond.) (1999) [Pubmed]
  5. Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine. Foster, S.A., Cerny, J., Cheng, Y.C. J. Biol. Chem. (1991) [Pubmed]
  6. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Schuetz, J.D., Connelly, M.C., Sun, D., Paibir, S.G., Flynn, P.M., Srinivas, R.V., Kumar, A., Fridland, A. Nat. Med. (1999) [Pubmed]
  7. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Balzarini, J., Naesens, L., Herdewijn, P., Rosenberg, I., Holy, A., Pauwels, R., Baba, M., Johns, D.G., De Clercq, E. Proc. Natl. Acad. Sci. U.S.A. (1989) [Pubmed]
  8. Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activity. Biessen, E.A., Valentijn, A.R., De Vrueh, R.L., Van De Bilt, E., Sliedregt, L.A., Prince, P., Bijsterbosch, M.K., Van Boom, J.H., Van Der Marel, G.A., Abrahams, P.J., Van Berkel, T.J. FASEB J. (2000) [Pubmed]
  9. Enhanced 9-(2-phosphonylmethoxyethyl)adenine secretion by a specific, indomethacin-sensitive efflux pump in a mutant 9-(2-phosphonylmethoxyethyl)adenine-resistant human erythroleukemia K562 cell line. Hatse, S., De Clercq, E., Balzarini, J. Mol. Pharmacol. (1998) [Pubmed]
  10. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. Bestman-Smith, J., Boivin, G. J. Virol. (2003) [Pubmed]
  11. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Mulato, A.S., Lamy, P.D., Miller, M.D., Li, W.X., Anton, K.E., Hellmann, N.S., Cherrington, J.M. Antimicrob. Agents Chemother. (1998) [Pubmed]
  12. Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice. Balzarini, J., Vahlenkamp, T., Egberink, H., Hartmann, K., Witvrouw, M., Pannecouque, C., Casara, P., Navé, J.F., De Clercq, E. Antimicrob. Agents Chemother. (1997) [Pubmed]
  13. Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine. Smith, M.S., Brian, E.L., De Clercq, E., Pagano, J.S. Antimicrob. Agents Chemother. (1989) [Pubmed]
  14. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Naesens, L., Balzarini, J., Bischofberger, N., De Clercq, E. Antimicrob. Agents Chemother. (1996) [Pubmed]
  15. Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Lin, C.C., Fang, C., Benetton, S., Xu, G.F., Yeh, L.T. Antimicrob. Agents Chemother. (2006) [Pubmed]
  16. Impact of 9-(2-phosphonylmethoxyethyl)adenine on (deoxy)ribonucleotide metabolism and nucleic acid synthesis in tumor cells. Hatse, S., De Clercq, E., Balzarini, J. FEBS Lett. (1999) [Pubmed]
  17. 9-(2-Phosphonylmethoxyethyl)adenine induces tumor cell differentiation or cell death by blocking cell cycle progression through the S phase. Hatse, S., Schols, D., De Clercq, E., Balzarini, J. Cell Growth Differ. (1999) [Pubmed]
  18. Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines. Perno, C.F., Balestra, E., Aquaro, S., Panti, S., Cenci, A., Lazzarino, G., Tavazzi, B., Di Pierro, D., Balzarini, J., Calio, R. Mol. Pharmacol. (1996) [Pubmed]
  19. Evidence for distinction of the differentiation-inducing activities and cytostatic properties of 9-(2-phosphonylmethoxyethyl)adenine and a variety of differentiation-inducing agents in human erythroleukemia K562 cells. Hatse, S., De Clercq, E., Balzarini, J. Mol. Pharmacol. (1996) [Pubmed]
  20. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Robbins, B.L., Greenhaw, J., Connelly, M.C., Fridland, A. Antimicrob. Agents Chemother. (1995) [Pubmed]
  21. The human immunodeficiency virus(HIV) inhibitor 9-(2-phosphonylmethoxyethyl)adenine (PMEA) is a strong inducer of differentiation of several tumor cell lines. Balzarini, J., Verstuyf, A., Hatse, S., Goebels, J., Sobis, H., Vandeputte, M., De Clercq, E. Int. J. Cancer (1995) [Pubmed]
  22. Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia. Dallas, S., Schlichter, L., Bendayan, R. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  23. High recombinagenic activities of three antiviral agents, adenine derivatives, in the Drosophila wing spot test. Marec, F., Gelbic, I. Mutat. Res. (1994) [Pubmed]
  24. Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine. Starrett, J.E., Tortolani, D.R., Hitchcock, M.J., Martin, J.C., Mansuri, M.M. Antiviral Res. (1992) [Pubmed]
  25. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. Balzarini, J., Naesens, L., Slachmuylders, J., Niphuis, H., Rosenberg, I., Holý, A., Schellekens, H., De Clercq, E. AIDS (1991) [Pubmed]
  26. Transplacental antiretroviral therapy with 9-(2-phosphonylmethoxyethyl)adenine is embryotoxic in transgenic mice. Lee, J.S., Mullaney, S., Bronson, R., Sharpe, A.H., Jaenisch, R., Balzarini, J., De Clercq, E., Ruprecht, R.M. J. Acquir. Immune Defic. Syndr. (1991) [Pubmed]
  27. Single-dose pharmacokinetics and metabolism of [14C]remofovir in rats and cynomolgus monkeys. Lin, C.C., Xu, C., Zhu, N., Lourenco, D., Yeh, L.T. Antimicrob. Agents Chemother. (2005) [Pubmed]
  28. Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates. Gong, Y.F., Marshall, D.R., Srinivas, R.V., Fridland, A. Antimicrob. Agents Chemother. (1994) [Pubmed]
  29. Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl) adenine in cynomolgus monkeys. Cundy, K.C., Shaw, J.P., Lee, W.A. Antimicrob. Agents Chemother. (1994) [Pubmed]
  30. Determination of adefovir in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Bi, H.C., Zhong, G.P., Zhou, S., Chen, X., Huang, M. Rapid Commun. Mass Spectrom. (2005) [Pubmed]
  31. Cryopreservation enables long-term storage of 9-(2-phosphonylmethoxyethyl)adenine prodrug-loaded reconstituted lactosylated high-density lipoprotein. de Vrueh, R.L., van Berkel, T.J., Bijsterbosch, M.K. Pharm. Res. (2001) [Pubmed]
 
WikiGenes - Universities